01 December 2004
Cardiovascular protection with ace inhibitors--more HOPE for EUROPA?
Christopher J. BoosMed Sci Monit 2004; 10(12): SR23-28 :: ID: 13240
Abstract
BACKGROUND: Treatment with angiotensin converting enzyme (ACE) inhibitors reduces mortality and morbidity among patients with heart failure, left-ventricular dysfunction after myocardial infarction and with hypertension. In addition, they have been shown to slow the progression of chronic kidney disease and reduce the recurrence of stroke and vascular events. MATERIAL/METHODS: There has been an enormous interest in the potential cardioprotective effects of ACE inhibitors. This principle has been assessed in two landmark double blind placebo controlled clinical trials, HOPE and EUROPA. This article seeks to review and compare the important findings of these two clinical studies. RESULTS: In the HOPE study, ramipril once daily produced a 22% reduction in the primary composite endpoint of myocardial infarction, stroke, or cardiovascular death (P < 0.001) among an older cohort (>55 years) of patients at high risk of future cardiovascular complications. The EUROPA study assessed the effects of the ACE inhibitor perindopril in a larger group of lower risk patients with established stable cardiovascular disease. In EUROPA, once daily treatment with perindopril lead to a significant 20% relative risk reduction in the combined primary endpoint (cardiovascular mortality, non-fatal myocardial infarction, and resuscitated cardiac arrest; p = 0.0003). CONCLUSIONS: HOPE and EUROPA provide compelling evidence to suggest that all patients with evidence of stable cardiovascular disease or diabetes (plus one additional risk factor) should be treated with an ACE inhibitor.
Keywords: Perindopril - therapeutic use, Ramipril - therapeutic use, Angiotensin-Converting Enzyme Inhibitors - therapeutic use, Cardiovascular Diseases - prevention & control, Controlled Clinical Trials as Topic, Perindopril - therapeutic use, Ramipril - therapeutic use
Editorial
01 April 2024 : Editorial
Editorial: Forty Years of Waiting for Prevention and Cure of HIV Infection – Ongoing Challenges and Hopes for Vaccine Development and Overcoming Antiretroviral Drug ResistanceDOI: 10.12659/MSM.944600
Med Sci Monit 2024; 30:e944600
In Press
06 Mar 2024 : Clinical Research
Comparison of Outcomes between Single-Level and Double-Level Corpectomy in Thoracolumbar Reconstruction: A ...Med Sci Monit In Press; DOI: 10.12659/MSM.943797
21 Mar 2024 : Meta-Analysis
Economic Evaluation of COVID-19 Screening Tests and Surveillance Strategies in Low-Income, Middle-Income, a...Med Sci Monit In Press; DOI: 10.12659/MSM.943863
10 Apr 2024 : Clinical Research
Predicting Acute Cardiovascular Complications in COVID-19: Insights from a Specialized Cardiac Referral Dep...Med Sci Monit In Press; DOI: 10.12659/MSM.942612
06 Mar 2024 : Clinical Research
Enhanced Surgical Outcomes of Popliteal Cyst Excision: A Retrospective Study Comparing Arthroscopic Debride...Med Sci Monit In Press; DOI: 10.12659/MSM.941102
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952